- CVS
- NVDA
- ^GSPC
One of the hotter stocks in big healthcare just now is pharmacy chain mainstay CVS Health (NYSE: CVS). The company’s shares have raced more than 18% higher year to date, comparing favorably to the benchmark S&P 500 index’s sub-13% rise.
And, according to most analysts tracking the stock, the stock’s not done yet. According to data compiled by TipRanks, the consensus pundit price target is $114.59 per share, which is 22% above its most recent closing level.
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a “Double Down” signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same “Total Conviction” signal is flashing for a company 1/100th the size of Nvidia. Continue »
Let’s open the doors of this busy pharmacy to determine how it got here, and whether it can indeed continue to move higher.
Beating analysts’ earning estimates
Any company that delivers two estimates-crushing quarters in a row is going to be a juicy buy candidate for investors. In all three of the quarterly earnings reports that CVS published this calendar year, it topped consensus analyst estimates for revenue and profitability. Investors are more impressed by the latter, naturally, so the company looked particularly good with its convincing beats in both the first and second frames.
First-quarter net income not under generally accepted accounting principles (non-GAAP, or adjusted) came in at $2.57 per share against the analyst consensus of $2.21. The gap for the following reporting period was much wider, at $2.58 and $1.83, respectively. Better — since stocks trade on future potential instead of trailing performance — CVS raised both its top- and bottom-line guidance in each of those two quarters.
What’s going right for CVS? A major factor is its healthcare benefits segment, anchored by giant insurer Aetna, which saw a sharp drop in its medical benefit ratio (MBR) in the first quarter. The MBR is a key metric in the health insurance field, as it measures the percentage of collected premiums that are paid out for claims (so a lower figure is better for CVS).
The company’s fourth quarter of 2025 MBR was 94.8%, then swooned to 84.6% before increasing modestly to 87.4% in the two subsequent periods. Keeping more premium money positively affected profitability: Adjusted operating income for healthcare benefits rose 52% year over year in the first quarter to over $3 billion, and 85% in the second quarter to $2.4 billion.
